Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML.
Othman J, Potter N, Ivey A, Tazi Y, Papaemmanuil E, Jovanovic J, Freeman SD, Gilkes AF, Gale RE, Rapoz-D'Silva T, Runglall M, Kleeman M, Dhami P, Thomas I, Johnson S, Canham J, Cavenagh JD, Kottaridis P, Arnold C, Ommen HB, Overgaard UM, Dennis M, Burnett AK -, Wilhelm-Benartzi CS, Huntly BJ, Russell NH, Dillon RJ. Othman J, et al. Among authors: runglall m. Blood. 2024 May 1:blood.2024024310. doi: 10.1182/blood.2024024310. Online ahead of print. Blood. 2024. PMID: 38691678
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.
Othman J, Potter N, Ivey A, Jovanovic J, Runglall M, Freeman SD, Gilkes A, Thomas I, Johnson S, Canham J, Cavenagh J, Kottaridis P, Arnold C, Ommen HB, Overgaard UM, Dennis M, Burnett A, Wilhelm-Benartzi C, Dillon R, Russell NH. Othman J, et al. Among authors: runglall m. Blood. 2024 May 9;143(19):1931-1936. doi: 10.1182/blood.2023023096. Blood. 2024. PMID: 38364112
Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome.
Loo S, Dillon R, Ivey A, Anstee NS, Othman J, Tiong IS, Potter N, Jovanovic J, Runglall M, Chong CC, Bajel A, Ritchie D, Gray K, Yeoh ZH, McBean M, Gilkes A, Thomas I, Johnson S, Russell NH, Wei AH. Loo S, et al. Among authors: runglall m. Blood. 2022 Dec 1;140(22):2407-2411. doi: 10.1182/blood.2022016567. Blood. 2022. PMID: 35960851 Free PMC article. No abstract available.
Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature.
Alimam S, Villiers W, Dillon R, Simpson M, Runglall M, Smith A, Chatzikyriakou P, Lavender P, Kanda A, Mills K, Bellosillo Paricio B, Kaufman-Cook J, Ord S, Kordasti S, Radia D, Woodley C, Francis Y, Mufti G, McLornan DP, Harrison CN. Alimam S, et al. Among authors: runglall m. Blood Adv. 2021 Feb 23;5(4):1059-1068. doi: 10.1182/bloodadvances.2020003172. Blood Adv. 2021. PMID: 33599741 Free PMC article.
Development and validation of the first consensus gene-expression signature of operational tolerance in kidney transplantation, incorporating adjustment for immunosuppressive drug therapy.
Christakoudi S, Runglall M, Mobillo P, Rebollo-Mesa I, Tsui TL, Nova-Lamperti E, Taube C, Norris S, Kamra Y, Hilton R, Augustine T, Bhandari S, Baker R, Berglund D, Carr S, Game D, Griffin S, Kalra PA, Lewis R, Mark PB, Marks SD, MacPhee I, McKane W, Mohaupt MG, Paz-Artal E, Kon SP, Serón D, Sinha MD, Tucker B, Viklický O, Stahl D, Lechler RI, Lord GM, Hernandez-Fuentes MP. Christakoudi S, et al. Among authors: runglall m. EBioMedicine. 2020 Aug;58:102899. doi: 10.1016/j.ebiom.2020.102899. Epub 2020 Jul 21. EBioMedicine. 2020. PMID: 32707447 Free PMC article.
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
Tiong IS, Dillon R, Ivey A, Teh TC, Nguyen P, Cummings N, Taussig DC, Latif AL, Potter NE, Runglall M, Russell NH, Raj K, Schwarer AP, Fong CY, Grigg AP, Wei AH. Tiong IS, et al. Among authors: runglall m. Br J Haematol. 2021 Mar;192(6):1026-1030. doi: 10.1111/bjh.16722. Epub 2020 May 26. Br J Haematol. 2021. PMID: 32458446 Free PMC article.
Molecular MRD status and outcome after transplantation in NPM1-mutated AML.
Dillon R, Hills R, Freeman S, Potter N, Jovanovic J, Ivey A, Kanda AS, Runglall M, Foot N, Valganon M, Khwaja A, Cavenagh J, Smith M, Ommen HB, Overgaard UM, Dennis M, Knapper S, Kaur H, Taussig D, Mehta P, Raj K, Novitzky-Basso I, Nikolousis E, Danby R, Krishnamurthy P, Hill K, Finnegan D, Alimam S, Hurst E, Johnson P, Khan A, Salim R, Craddock C, Spearing R, Gilkes A, Gale R, Burnett A, Russell NH, Grimwade D. Dillon R, et al. Among authors: runglall m. Blood. 2020 Feb 27;135(9):680-688. doi: 10.1182/blood.2019002959. Blood. 2020. PMID: 31932839 Free PMC article. Clinical Trial.
Development of a multivariable gene-expression signature targeting T-cell-mediated rejection in peripheral blood of kidney transplant recipients validated in cross-sectional and longitudinal samples.
Christakoudi S, Runglall M, Mobillo P, Tsui TL, Duff C, Domingo-Vila C, Kamra Y, Delaney F, Montero R, Spiridou A, Kassimatis T, Phin-Kon S, Tucker B, Farmer C, Strom TB, Lord GM, Rebollo-Mesa I, Stahl D, Sacks S, Hernandez-Fuentes MP, Chowdhury P. Christakoudi S, et al. Among authors: runglall m. EBioMedicine. 2019 Mar;41:571-583. doi: 10.1016/j.ebiom.2019.01.060. Epub 2019 Mar 2. EBioMedicine. 2019. PMID: 30833191 Free PMC article.
Steroid regulation: An overlooked aspect of tolerance and chronic rejection in kidney transplantation.
Christakoudi S, Runglall M, Mobillo P, Rebollo-Mesa I, Tsui TL, Nova-Lamperti E, Norris S, Kamra Y, Hilton R, Bhandari S, Baker R, Berglund D, Carr S, Game D, Griffin S, Kalra PA, Lewis R, Mark PB, Marks SD, Macphee I, McKane W, Mohaupt MG, Pararajasingam R, Kon SP, Serón D, Sinha M, Tucker B, Viklický O, Lechler RI, Lord GM, Stahl D, Hernandez-Fuentes MP. Christakoudi S, et al. Among authors: runglall m. Mol Cell Endocrinol. 2018 Sep 15;473:205-216. doi: 10.1016/j.mce.2018.01.021. Epub 2018 Feb 7. Mol Cell Endocrinol. 2018. PMID: 29427591 Free article.
22 results